series-b
Stage
1
Investors
About
Sagitta Biotech develops active virosome technology based on a modified measles virus for fast and flexible production of vaccines, targeted cancer immunotherapies, and gene therapies.
Explore Sagitta Biotech's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.